ÂÜÀòÂÒÂ×

David Martin has extensive experience in the biotechnology and pharmaceutical industries, currently serving as CEO of Pylum Biosciences, Inc. since December 2017 and as CEO of AvidBiotics Corp. since 2005. Previous leadership roles include CEO positions at Eos Biotechnology (1996-2003), Lynx, Inc. (1995-1996), and President at Chiron Therapeutics (1994-1995). Prior roles include Executive Vice President of Research and Development at DuPont-Merck (1991-1994) and Senior Vice President of Research and Development at Genentech (1983-1990). David Martin began a distinguished academic career as a Howard Hughes Investigator and Professor of Medicine and Biochemistry at UCSF Medical Center from 1969 to 1982. David Martin holds an MD from MIT and Duke Medical School, specializing in internal medicine and medical genetics.